890 F.3d 1313
Fed. Cir.2018Background
- UCB owns U.S. Patent No. RE38,551 covering lacosamide (Vimpat®), an R‑enantiomer anti‑epileptic; lacosamide claims include purity (≥90% R) and specific substituents at R (unsubstituted benzyl), R1 (unsubstituted methyl), and R3 (methoxymethyl).
- Generic manufacturers filed ANDAs with Paragraph IV certifications; UCB sued for infringement; defendants stipulated infringement of asserted claims (9, 10, 13) and defended on invalidity grounds (obviousness‑type double patenting, obviousness, anticipation).
- Prior art includes Kohn publications and U.S. Patent No. 5,378,729 ('729) and its CIP 5,654,301 ('301). The '301 patent claims a broad FAA genus; claim 45 narrows R3 to methoxymethyl but leaves R and R1 generic (which can include benzyl and methyl).
- LeGall thesis discloses racemic compound 107e (same substituents as lacosamide but racemate) without direct efficacy data for 107e; some prior FAA work favored heteroaromatic R3 groups and reported many compounds with benzyl at R and methyl at R1.
- District court found asserted claims not invalid: no reasonable expectation of success to arrive at lacosamide from the '301 genus (double patenting), no prima facie obviousness (lead‑compound analysis and lack of motivation/expectation), and no anticipation by LeGall (racemate does not disclose a specific enantiomer).
- Federal Circuit affirms: reviews legal conclusions de novo, fact findings for clear error; holds district court applied correct standards and did not clearly err in factual findings supporting non‑invalidity.
Issues
| Issue | UCB's Argument (Plaintiff) | Appellants' Argument (Defendant) | Held |
|---|---|---|---|
| Obviousness‑type double patenting | Claims must be considered as a whole; differences between patents (R, R1) plus whole‑claim context show patentable distinctness | Asserted species (lacosamide) is obvious from '301 genus (claim 45) — species falls within genus and is not patentably distinct | Affirmed: district court did not clearly err; no reasonable expectation of success to combine benzyl+methyl with methoxymethyl at R3, so claims patentably distinct |
| Obviousness (§103) | No lead‑compound selection: asserted compound is not obvious because prior art lacked motivation/expectation to select racemate or nonaromatic R3 compounds as leads | LeGall or LeGall+'729/Kohn would render lacosamide obvious (or purifying racemate to R enantiomer is routine) | Affirmed: district court permissibly used lead‑compound analysis (or alternatively showed no expectation); prior art would not have led a skilled artisan to select 107e/3l as a lead with reasonable expectation of success |
| Anticipation (§102) | N/A for plaintiff (UCB argued not anticipated) | LeGall's disclosure of racemate 107e anticipates lacosamide because racemate necessarily discloses enantiomers | Affirmed: LeGall did not disclose separation, identification, or characteristics of the R‑enantiomer; a racemate disclosure alone does not anticipate a specific enantiomer |
| Evidentiary/burden issues (enablement/expectation) | Genus enablement does not preclude finding lack of reasonable expectation of success for a species | Genus claim or listing of benzyl/methyl as preferred creates presumption of enablement and expectation of success | Held: presumption of genus enablement does not negate fact question whether skilled artisan had reasonable expectation of success; district court's factual finding stands |
Key Cases Cited
- Microsoft Corp. v. i4i Ltd. P'ship, 564 U.S. 91 (clear‑and‑convincing evidence standard for invalidity)
- Sanofi‑Synthelabo v. Apotex, Inc., 550 F.3d 1075 (Fed. Cir.) (racemate disclosure does not necessarily anticipate specific enantiomer)
- Otsuka Pharm. Co. v. Sandoz, Inc., 678 F.3d 1280 (Fed. Cir.) (double patenting doctrine and reasonable expectation of success inquiry)
- AbbVie Inc. v. Mathilda & Terence Kennedy Inst., 764 F.3d 1366 (Fed. Cir.) (double patenting two‑step test: compare claims then assess patentable distinctness)
- Eli Lilly & Co. v. Teva Parenteral Medicines, Inc., 689 F.3d 1368 (Fed. Cir.) (consider claims "as a whole" in double patenting/obviousness analyses)
- Amgen Inc. v. F. Hoffman‑La Roche Ltd., 580 F.3d 1340 (Fed. Cir.) (reasonable expectation of success required for obviousness)
- Aventis Pharma Deutschland GmbH v. Lupin, Ltd., 499 F.3d 1293 (Fed. Cir.) (purified stereoisomer over racemate — when purification is prima facie obvious)
- Par Pharm., Inc. v. TWI Pharm., Inc., 773 F.3d 1186 (Fed. Cir.) (reasonable expectation of success is a factual question reviewed for clear error)
- In re Longi, 759 F.2d 887 (Fed. Cir.) (double patenting prevents extension of patent term)
- In re May, 574 F.2d 1082 (CCPA) (novelty of optical isomer not negated by prior racemate disclosure)
- Pfizer, Inc. v. Apotex, Inc., 480 F.3d 1348 (Fed. Cir.) (reasonable probability/expectation of success in unpredictable arts)